• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Stat1 缺失会减少巨核细胞生成,并有利于 JAK2-V617F 驱动的骨髓增殖性肿瘤小鼠模型中的红细胞生成。

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.

机构信息

Department of Biomedicine, Experimental Hematology and.

Institute of Pathology, University Hospital Basel, Basel, Switzerland.

出版信息

Blood. 2014 Jun 19;123(25):3943-50. doi: 10.1182/blood-2013-07-514208. Epub 2014 May 12.

DOI:10.1182/blood-2013-07-514208
PMID:24820309
Abstract

The interferon-γ (IFNγ)/signal transducer and activator of transcription 1 (Stat1) pathway shows higher activity in patients with essential thrombocythemia (ET) than in polycythemia vera (PV) and was proposed to be promoting the ET phenotype. We explored the phenotypic consequences of Stat1 deficiency on the effects of Janus kinase 2 (JAK2)-V617F in vivo by crossing mice expressing JAK2-V617F with Stat1 knockout mice. JAK2-V617F;Stat1(-/-) double transgenic mice showed higher red cell parameters and lower platelet counts compared with JAK2-V617F;Stat1(+/+) mice. Bone marrow transplantation reproduced these phenotypic changes in wild-type recipients, demonstrating that the effect of Stat1 is cell-intrinsic and does not require a Stat1-deficient microenvironment. Deletion of Stat1 increased burst-forming unit-erythroid and reduced colony-forming unit-megakaryocyte colony formation driven by JAK2-V617F, but was not sufficient to completely normalize the platelet count. Gata1, a key regulator of megakaryopoiesis and erythropoiesis, was decreased in Stat1-deficient platelets. V617F transgenic mice with thrombocytosis had higher serum levels of IFNγ than normal controls and patients with ET showed higher IFNγ serum levels than patients with PV. Together, these results support the concept that activating Stat1 in the presence of JAK2-V617F, for example, through IFNγ, constrains erythroid differentiation and promotes megakaryocytic development, resulting in ET phenotype.

摘要

干扰素-γ (IFNγ)/信号转导和转录激活因子 1 (Stat1) 途径在原发性血小板增多症 (ET) 患者中的活性高于真性红细胞增多症 (PV),并被提议促进 ET 表型。我们通过将表达 JAK2-V617F 的小鼠与 Stat1 敲除小鼠杂交,探索了 Stat1 缺陷对体内 JAK2-V617F 影响的表型后果。JAK2-V617F;Stat1(-/-)双转基因小鼠的红细胞参数较高,血小板计数较低,与 JAK2-V617F;Stat1(+/+)小鼠相比。骨髓移植在野生型受体中再现了这些表型变化,表明 Stat1 的作用是细胞内的,不需要 Stat1 缺陷的微环境。Stat1 的缺失增加了 JAK2-V617F 驱动的红系爆式集落形成单位和减少了巨核细胞集落形成单位,但不足以完全使血小板计数正常化。Gata1 是巨核细胞生成和红细胞生成的关键调节因子,在 Stat1 缺陷的血小板中减少。血小板增多的 V617F 转基因小鼠的血清 IFNγ 水平高于正常对照,而 ET 患者的 IFNγ 血清水平高于 PV 患者。总之,这些结果支持这样一种概念,即在存在 JAK2-V617F 的情况下激活 Stat1,例如通过 IFNγ,限制了红细胞分化并促进了巨核细胞的发育,从而导致 ET 表型。

相似文献

1
Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.Stat1 缺失会减少巨核细胞生成,并有利于 JAK2-V617F 驱动的骨髓增殖性肿瘤小鼠模型中的红细胞生成。
Blood. 2014 Jun 19;123(25):3943-50. doi: 10.1182/blood-2013-07-514208. Epub 2014 May 12.
2
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.JAK2 V617F突变、自发性红细胞生成和巨核细胞生成、高敏血小板、活化白细胞以及内皮细胞在真性红细胞增多症和原发性血小板增多症血栓形成表现病因中的作用。
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):381-98. doi: 10.1055/s-2006-942759.
3
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.JAK2 V617F 诱导小鼠发生红细胞增多症的分子发病机制与治疗
PLoS One. 2006 Dec 20;1(1):e18. doi: 10.1371/journal.pone.0000018.
4
Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.造血细胞中 Stat3 的缺失可增强 JAK2-V617F 小鼠模型中骨髓增殖性肿瘤的血小板增多症并缩短其生存期。
Blood. 2015 Mar 26;125(13):2131-40. doi: 10.1182/blood-2014-08-594572. Epub 2015 Jan 16.
5
Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.V617F 和 exon12 突变 JAK2 表达对基于人诱导多能干细胞(iPSC)模型的红细胞生成的不同影响。
Sci Rep. 2021 Mar 4;11(1):5255. doi: 10.1038/s41598-021-83895-6.
6
Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.真性红细胞增多症和伴有JAK2 V617F突变的原发性血小板增多症患者的巨核细胞生成和血小板功能
Int J Hematol. 2008 Sep;88(2):181-188. doi: 10.1007/s12185-008-0129-9. Epub 2008 Jul 10.
7
JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.JAK2 V617F通过激活Stat1和其他非红系信号通路,刺激促红细胞生成素依赖的红系祖细胞增殖并延缓其分化。
Exp Hematol. 2016 Nov;44(11):1044-1058.e5. doi: 10.1016/j.exphem.2016.07.010. Epub 2016 Jul 26.
8
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.在表达JAK2 V617F的小鼠中真性红细胞增多症、原发性骨髓纤维化和血小板增多症的发展。
Leukemia. 2008 Jan;22(1):87-95. doi: 10.1038/sj.leu.2405043. Epub 2007 Nov 22.
9
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.JAK2 V617F 损害条件性敲入 JAK2 V617F 阳性原发性血小板增多症小鼠模型中造血干细胞的功能。
Blood. 2010 Sep 2;116(9):1528-38. doi: 10.1182/blood-2009-12-259747. Epub 2010 May 20.
10
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病(MPD)、原发性血小板增多症(ET)、真性红细胞增多症(PV)和慢性特发性骨髓纤维化(CIMF)的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.

引用本文的文献

1
Recent advances and future perspectives in small molecule JAK2 inhibitors.小分子JAK2抑制剂的最新进展与未来展望
Future Med Chem. 2025 May;17(10):1175-1191. doi: 10.1080/17568919.2025.2507564. Epub 2025 May 20.
2
Malignant JAK-signaling: at the interface of inflammation and malignant transformation.恶性JAK信号传导:炎症与恶性转化的交汇点
Leukemia. 2025 May;39(5):1011-1030. doi: 10.1038/s41375-025-02569-8. Epub 2025 Mar 26.
3
Molecular characterization underlying IFN-α2 treatment in polycythemia vera: a transcriptomic overview.
真性红细胞增多症中IFN-α2治疗的分子特征:转录组概述
Mol Cell Biochem. 2025 Mar 3. doi: 10.1007/s11010-025-05238-7.
4
Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins.骨髓增殖性肿瘤:由信号转导子和转录激活子(STAT)蛋白的慢性激活介导的疾病
Cancers (Basel). 2024 Jan 11;16(2):313. doi: 10.3390/cancers16020313.
5
Molecular Pathogenesis of Myeloproliferative Neoplasms.骨髓增殖性肿瘤的分子发病机制
Curr Hematol Malig Rep. 2022 Dec;17(6):319-329. doi: 10.1007/s11899-022-00685-1. Epub 2022 Nov 7.
6
Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.费城染色体阴性骨髓增殖性肿瘤:从造血干细胞到临床特征的分子历程
Medicina (Kaunas). 2021 Sep 30;57(10):1043. doi: 10.3390/medicina57101043.
7
Molecular pathogenesis of the myeloproliferative neoplasms.骨髓增殖性肿瘤的分子发病机制。
J Hematol Oncol. 2021 Jun 30;14(1):103. doi: 10.1186/s13045-021-01116-z.
8
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.骨髓增殖性肿瘤(MPN):疾病起始、进展和转化的分子驱动因素及其对治疗的影响。
Cells. 2020 Aug 14;9(8):1901. doi: 10.3390/cells9081901.
9
Novel targets to cure primary myelofibrosis from studies on Gata1 mice.从 Gata1 小鼠研究中寻找治疗原发性骨髓纤维化的新靶点。
IUBMB Life. 2020 Jan;72(1):131-141. doi: 10.1002/iub.2198. Epub 2019 Nov 21.
10
Molecular mechanisms of bleeding disorderassociated GFI1B mutation and its affected pathways in megakaryocytes and platelets.与出血性疾病相关的 GFI1B 突变及其在巨核细胞和血小板中的作用途径的分子机制。
Haematologica. 2019 Jul;104(7):1460-1472. doi: 10.3324/haematol.2018.194555. Epub 2019 Jan 17.